Ann: PAT-DX1 Conjugated to Nanoparticles, Targets Tumors, page-42

With 750 million shares on issue, if the SP is 10 cents the market cap will still be only $75 million, which is low if DX1 has some promise as further testing, anticipation and announcements and expectation of a major breakthrough will drive the SP higher.

To keep the SP in perspective the market cap of PRR is $50 million and that of objective is $80 million and both have nothing new to show soon at the moment. These are beaten down prices which were multiple times higher closer to announcements of their interim test results.

So 10 cents is achievable. That should see a small cap raising of $10 million with 1 for 7 rights issue for minimal dilution. Of course for this to happen management should keep the communication going and announce the details and dates of the upcoming testing and results.

GLTA brainy